A Pilot Study of AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 22 May 2017
At a glance
- Drugs AMP 224 (Primary) ; Cyclophosphamide
- Indications Colorectal cancer
- Focus Adverse reactions
- 07 Apr 2017 Status changed from active, no longer recruiting to completed.
- 03 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
- 03 Sep 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2017.